New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:14 EDTCPRXCatalyst Pharmaceutical announces dismissal of stockholder class action lawsuit
Catalyst Pharmaceutical announced that on January 3, the previously reported stockholder class action lawsuit that had been filed against Catalyst and certain of its officers and directors was dismissed without prejudice. In the Court's order, the plaintiffs were granted leave to file an amended complaint within 20 days. Catalyst has no information as to whether any such amended complaint is planned by the plaintiffs. If an amended complaint is filed in the case, Catalyst intends to vigorously defend the amended lawsuit.
News For CPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
11:18 EDTCPRXCatalyst Pharmaceutical shares undervalued, says H.C. Wainwright
09:10 EDTCPRXOn The Fly: Pre-market Movers
Subscribe for More Information
05:41 EDTCPRXCatalyst Pharmaceutical to host conference call
Conference call to discuss positive top-line results from the Firdapse clinical trial will be held on September 30 at 8:30 am. Webcast Link
September 29, 2014
18:22 EDTCPRXOn The Fly: After Hours Movers
Subscribe for More Information
17:08 EDTCPRXCatalyst Pharmaceutical up 24% after hours following positive Firdapse data
16:05 EDTCPRXCatalyst Pharmaceutical: Results from Phase 3 trial of Firdapse met co-endpoints
Catalyst Pharmaceutical announced positive top-line results from the pivotal Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Both co-primary endpoints, quantitative myasthenia gravis score and subject global impression, demonstrated that Firdapse was significantly superior to placebo, as did a secondary endpoint for the physician's clinical global impression of improvement. This clinical trial was designed as a double blind, randomized, "withdrawal trial" in which all patients were initially treated with Firdapse during a 91 day run-in period followed by treatment with either Firdapse or placebo during a 2 week randomization period. A total of 38 patients completed the 3 month run-in period and subsequent 2 week randomization period. In a trial of this design, the clinically significant findings, when present, are worsening of symptoms in the placebo group.
16:00 EDTCPRXCatalyst Pharmaceutical trading halted, pending news
Subscribe for More Information
09:53 EDTCPRXCatalyst Pharmaceutical management to meet with Roth Capital
Meeting to be held in San Francisco on October 6 hosted by Roth Capital.
September 16, 2014
09:00 EDTCPRXCatalyst Pharmaceutical price target raised to $5 from $3.50 at Roth Capital
Roth Capital increased its price target on Catalyst to reflect what it sees as greater pricing power opportunities for Firdapse and the re-entry of CPP-115 into the clinic. Evaluating the potential outcome of a Phase 3 trial of Firdapse expected at the end of this month, the firm says the decision by all patients enrolled to continue treatment in the 2-year open label part of the trial is positive. However, Roth warns that the data poses a binary risk to the stock. It keeps a Buy rating on the shares. .

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use